Literature DB >> 2661260

Sympathomimetics in acute severe asthma: inhaled or parenteral, nebulizer or spacer?

A Noseda1, J C Yernault.   

Abstract

It is accepted today that all patients with acute asthma should be treated with a sympathomimetic, irrespective of previous therapy. This short review addresses the question of the optimal mode of administration of these drugs in acute severe asthma. Inhaled sympathomimetics are as effective as subcutaneous adrenaline, or intravenous salbutamol or terbutaline, and, as they produce fewer side-effects, are recommended as the best mode of administration. However, self-medication with a ready to use subcutaneous preparation may be indicated in those patients prone to very abrupt attacks. The conventional mode of inhalation therapy in acute asthma is nebulization, but equally effective bronchodilatation may be obtained with metered-dose inhalers combined with valved spacers. Tachypnoeic patients unable to perform a conventional inhalation manoeuvre can use one-way valve inhalation devices with repeated tidal breaths. Finally, sequential or even continuous inhalation techniques have recently been advocated, particularly in patients with impending respiratory failure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2661260

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

Review 1.  Risk/benefit ratio of long-term treatment with beta 2-adrenoceptor agonists.

Authors:  I Ziment
Journal:  Lung       Date:  1990       Impact factor: 2.584

2.  Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer.

Authors:  B J Lipworth; D J Clark
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

Review 3.  Spacer devices for metered dose inhalers.

Authors:  Stephen P Newman
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 4.  The effect of respiratory disorders on clinical pharmacokinetic variables.

Authors:  A M Taburet; C Tollier; C Richard
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 5.  Pharmacokinetic optimisation of asthma treatment.

Authors:  A M Taburet; B Schmit
Journal:  Clin Pharmacokinet       Date:  1994-05       Impact factor: 6.447

Review 6.  Emergency management of acute adult asthma.

Authors:  A F Grunfeld; K Ho
Journal:  Can Fam Physician       Date:  1995-11       Impact factor: 3.275

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.